MarketPulse

Phase 3 trials

31 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma A/S

Zealand Pharma Surges on Obesity Drug Breakthroughs and $700M Revenue Milestone

Zealand Pharma reports strong Q1 2026 results with obesity treatment advances, $700M collaboration revenue, and $200M share buyback program.
RHHBYZLDPYPhase 3 trialsclinical trial results
The Motley FoolThe Motley Fool··James Brumley

Viking Therapeutics Stock Could Double as GLP-1 Rival Advances Toward FDA Approval

Wall Street projects 170% upside for Viking Therapeutics' obesity drug candidate VK2735, citing superior weight loss and tolerability versus Novo Nordisk and Eli Lilly rivals.
LLYNVOVKTXFDA approvalPhase 3 trials
BenzingaBenzinga··Prnewswire

Viking Therapeutics to Report Q1 2026 Results; Obesity Drug VK2735 in Focus

Viking Therapeutics will report Q1 2026 earnings April 29 after market close, showcasing progress on obesity and metabolic disorder treatments.
VKTXfinancial resultsPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx Expands VYVGART Leadership with Positive Phase 3 Data Across MG and CIDP

argenx presents Phase 3 data supporting VYVGART expansion across ocular MG, seronegative MG, and treatment-naïve CIDP, with 87.5% early benefit rates.
ARGXFDA approvalPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 clinical trials. Investors can join by April 6, 2026.
MREOsecurities fraudclass action lawsuit
BenzingaBenzinga··Vandana Singh

AstraZeneca Splits on HPP Drug as COPD Candidate Advances

AstraZeneca's efzimfotase alfa succeeds in pediatric HPP trials but fails in adults. Meanwhile, tozorakimab meets COPD endpoints across smoker populations.
AZNPhase 3 trialsCOPD
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Alumis' Psoriasis Drug Shows Strong Phase 3 Results, Paving Way for 2026 FDA Filing

Alumis reports positive Phase 3 results for envudeucitinib, achieving 68% PASI 90 skin clearance in plaque psoriasis patients, with FDA filing planned for late 2026.
ALMSquality of lifeTYK2 inhibitor
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials, $MREO Investors Urged to Act

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 trials ORBIT and COSMIC; investors in $MREO securities from June 2023-December 2025 urged to act by April 6, 2026 deadline.
MREOsecurities fraudclass action lawsuit
BenzingaBenzinga··Vandana Singh

AstraZeneca Powers Ahead in COPD with Blockbuster Trial Win, Eyes $3-5B Peak Sales

AstraZeneca's tozorakimab shows positive Phase 3 COPD data, reducing exacerbations versus placebo. Stock rises 3.68% premarket; company forecasts $3-5B peak sales.
SNYAZNREGNmonoclonal antibodyPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials and Investor Losses

Mereo BioPharma faces class action lawsuit alleging misrepresentations regarding failed Phase 3 clinical trials, with lead plaintiff deadline April 6, 2026.
MREOsecurities fraudclass action lawsuit
The Motley FoolThe Motley Fool··Jonathan Ponciano

Viking Therapeutics Lands $7M Investment as Obesity Drug Pipeline Gains Momentum

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.
CVXVKTXKRYSABVXPhase 3 trialsclinical-stage biotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Olema Oncology Advances Breast Cancer Pipeline, Secures $218.5M in Funding

Olema reported strong trial progress for palazestrant in breast cancer, raised $218.5M, and expects pivotal data in fall 2026.
PFEOLMAPhase 3 trialsclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

EyePoint Grants Stock Options to New Hires as DURAVYU Phase 3 Trials Advance

EyePoint grants stock options to six new employees as clinical program advances toward Phase 3 topline data for wet AMD therapy.
EYPTPhase 3 trialsbiopharmaceutical
The Motley FoolThe Motley Fool··Jonathan Ponciano

EyePoint Pharmaceuticals Attracts $20M Strategic Investment Amid 93% Annual Surge

Parkman Healthcare Partners invests $20M in EyePoint Pharmaceuticals as shares surge 93% annually ahead of mid-2026 Phase 3 data for retinal disease treatment DURAVYU.
CVSDXCMEYPTPODDbiotechPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Lawsuit Over Failed Drug Trial Disclosures

Rosen Law Firm urges MREO investors to join class action over alleged misleading statements regarding setrusumab Phase 3 trial failures.
MREOinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials and Investor Losses

Class action lawsuit filed against Mereo BioPharma over alleged misstatements regarding failed Phase 3 clinical trials. Investors have until April 6, 2026, to join.
MREOsecurities fraudclass action lawsuit
BenzingaBenzinga··Vandana Singh

Eli Lilly Poised to Challenge AstraZeneca in Abivax Bidding War

AstraZeneca has exclusive access to Abivax data until March 23. If it misses deadline, Eli Lilly could rejoin bidding for French biotech valued by 1,600% surge.
LLYAZNABVXacquisitionbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Drug Trials and Misleading Statements

Mereo BioPharma faces class action over failed Phase 3 trials and alleged misleading statements. Investor deadline April 6, 2026.
MREOsecurities fraudclass action lawsuit
BenzingaBenzinga··Vandana Singh

BioNTech Plummets 14% as Co-Founders Exit for New mRNA Venture

BioNTech shares plunge 14% as co-founders announce exit plan, with company cutting 2026 revenue guidance due to declining COVID demand.
BMYCELGrPFEMRNABNTXguidance reductionPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Hit With Class Action Over Failed Clinical Trials and Misleading Statements

Class action filed against Mereo BioPharma over allegedly false statements regarding failed Phase 3 clinical trials, covering $MREO investors from June 2023 to December 2025.
MREOsecurities fraudclass action lawsuit